Literature DB >> 31788115

Differences in the early stage gene expression profiles of lung adenocarcinoma and lung squamous cell carcinoma.

Nitin Venugopal1, Justin Yeh1, Sai Karthik Kodeboyina1, Tae Jin Lee1, Shruti Sharma1,2, Nikhil Patel3, Ashok Sharma1,4.   

Abstract

The discovery of lung carcinoma subtype-specific gene expression changes has the potential to elucidate the molecular differences and provide personalized therapeutic targets for these pathologies. The aim of the present study was to characterize the genetic profiles of the early stages (IA/IB) of two non-small cell lung cancer subtypes, adenocarcinoma (AD) and squamous cell carcinoma (SC). RNA-Seq gene expression data from The Cancer Genome Atlas was analyzed to compare the gene expression differences between AD and SC. The gene sets specific to each subtype were further analyzed to identify the enriched Gene Ontology terms, Kyoto Encyclopedia of Genes and Genomes pathways and biological functions. The results demonstrated that a unique set of genes (145 upregulated and 27 downregulated) was altered in AD, but not in SC; another set of genes (146 upregulated and 103 downregulated) was significantly altered in SC, but not in AD. Genes highly upregulated specifically in AD included albumin (1,732-fold), protein lin-28 homolog A, which is a positive regulator of cyclin-dependent kinase 2 (150-fold) and gastric lipase (81-fold). Genes highly upregulated specifically in SC included amelotin (618-fold), alcohol dehydrogenase 7 (57-fold), aclerosteosis (55-fold) and claudin-22 (54-fold). Several cancer/testis antigen family genes were notably upregulated in SC, but not in AD, whereas mucins were upregulated only in AD. Functional pathway analysis demonstrated that the dysregulation of genes associated with retinoid X receptors was common in AD and SC, genes associated with 'lipid metabolism' and 'drug metabolism' were dysregulated only in SC, whereas genes associated with 'molecular transport' and 'cellular growth and proliferation' were significantly enriched in AD specifically. These results reveal fundamental differences in the gene expression profiles of early-stage AD and SC. In addition, the present study identified molecular pathways that are uniquely associated with the pathogenesis of these subtypes. Copyright: © Venugopal et al.

Entities:  

Keywords:  The Cancer Genome Atlas; lung adenocarcinoma; lung squamous cell carcinoma; non-small cell lung cancer

Year:  2019        PMID: 31788115      PMCID: PMC6865721          DOI: 10.3892/ol.2019.11013

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  64 in total

1.  Gene expression analysis of lung cancer.

Authors:  W-Y Shi; K-D Liu; S-G Xu; J-T Zhang; L-L Yu; K-Q Xu; T-F Zhang
Journal:  Eur Rev Med Pharmacol Sci       Date:  2014       Impact factor: 3.507

2.  The Value of Cytokeratin 5/6, p63 and Thyroid Transcription Factor-1 in Adenocarcinoma, Squamous Cell Carcinoma and Non-Small-Cell Lung Cancer of the Lung.

Authors:  Asuman Argon; Deniz Nart; Ali Veral
Journal:  Turk Patoloji Derg       Date:  2015

3.  5,7-Dimethoxyflavone downregulates CYP1A1 expression and benzo[a]pyrene-induced DNA binding in Hep G2 cells.

Authors:  Xia Wen; U Kristina Walle; Thomas Walle
Journal:  Carcinogenesis       Date:  2005-01-20       Impact factor: 4.944

4.  Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras.

Authors:  Jee-Sun Oh; Jae-Jin Kim; Ju-Yeon Byun; In-Ah Kim
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-01-01       Impact factor: 7.038

5.  HNF4α as a marker for invasive mucinous adenocarcinoma of the lung.

Authors:  Masato Sugano; Toru Nagasaka; Eiichi Sasaki; Yoshiko Murakami; Waki Hosoda; Toyoaki Hida; Tetsuya Mitsudomi; Yasushi Yatabe
Journal:  Am J Surg Pathol       Date:  2013-02       Impact factor: 6.394

Review 6.  Mucins: a biologically relevant glycan barrier in mucosal protection.

Authors:  Anthony P Corfield
Journal:  Biochim Biophys Acta       Date:  2014-05-10

7.  SOSTDC1 is down-regulated in non-small cell lung cancer and contributes to cancer cell proliferation.

Authors:  Lei Liu; Shanshan Wu; Yi Yang; Junchao Cai; Xun Zhu; Jueheng Wu; Mengfeng Li; Hongyu Guan
Journal:  Cell Biosci       Date:  2016-04-14       Impact factor: 7.133

Review 8.  Next-generation sequencing technologies: breaking the sound barrier of human genetics.

Authors:  El Mustapha Bahassi; Peter J Stambrook
Journal:  Mutagenesis       Date:  2014-09       Impact factor: 3.000

9.  High expression of SMARCA4 or SMARCA2 is frequently associated with an opposite prognosis in cancer.

Authors:  Jose A Guerrero-Martínez; Jose C Reyes
Journal:  Sci Rep       Date:  2018-02-01       Impact factor: 4.379

Review 10.  The Aryl Hydrocarbon Receptor and Tumor Immunity.

Authors:  Ping Xue; Jinrong Fu; Yufeng Zhou
Journal:  Front Immunol       Date:  2018-02-13       Impact factor: 7.561

View more
  2 in total

1.  T2-DAG: a powerful test for differentially expressed gene pathways via graph-informed structural equation modeling.

Authors:  Jin Jin; Yue Wang
Journal:  Bioinformatics       Date:  2021-11-10       Impact factor: 6.937

2.  Comprehensive micro-scaled proteome and phosphoproteome characterization of archived retrospective cancer repositories.

Authors:  Corinna Friedrich; Simon Schallenberg; Marieluise Kirchner; Matthias Ziehm; Sylvia Niquet; Mohamed Haji; Christin Beier; Jens Neudecker; Frederick Klauschen; Philipp Mertins
Journal:  Nat Commun       Date:  2021-06-11       Impact factor: 14.919

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.